Project: From MoleculAr phenoTyping to personalized pharmaCotHerapy in cardiology - An interdisciplinary and translational approach towards precise pharmacotherapy in coronary heart disease

Acronym MATCH (Reference Number: ERAPERMED2018-226)
Duration 01/03/2019 - 28/02/2022
Project Topic Cardiovascular disease (CVD) represents the most important cause of morbidity and mortality in the EU and causes an enormous socioeconomic impact with 200 Billion Euros annual costs. Evidence-based medicine has considerably advanced the treatment of coronary heart disease (CHD), and its implementation was driven by multicenter interventional trials. However, most large-scale trials of the recent decade yielded only statistically significant differences in outcome with small overall efficacies that did not relevantly reduce the residual risk. Therefore, innovative approaches in order to overcome this concerning development and foster individualized pharmacotherapy in CHD are urgently needed. Within MATCH, we will take an interdisciplinary and translational approach integrating knowledge from comprehensive Omics-based molecular phenotype analyses, CAD epidemiology, imaging, bioinformatics, statistics and molecular biology. MATCH builds on existing individual-based phenotype-genotype data of distinct CHD trials, functional imaging data, epidemiological cohort data and biobanks, bioinformatical methodologies and animal models. Bioinformatics comprising machine-based learning models will generate a biomarker signature of responders versus non-responders across various cardiovascular lipid trials. This signature will be optimized in atherosclerosis-prone mouse models and human cohorts. The optimized signature will be validated in an existing second subset of cardiovascular trial participants and finally be translated in an ongoing imaging-based (OCT) trial longitudinally assessing the progress of atherosclerosis in subjects with CHD. MATCH will enable us to 1) pave the way for affordable tools of targeted treatment in cardiovascular disease, 2) to explore the molecular pathophysiology and signature of individual response to lipid-lowering therapy in a comprehensive view, and 3) apply personalized medicine to affected individuals using individualized pharmacotherapy.
Network ERA PerMed
Call 1st Joint Transnational Call for Proposals (2018)

Project partner

Number Name Role Country
1 University Medical Centre Hamburg Eppendorf Coordinator Germany
2 IRCCS San Raffaele, Pisana Partner Italy
3 INSERM Partner France
4 University Medical Center Göttingen Partner Germany